Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US... Show more
Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic information services, empowering people to achieve better health outcomes through clinical laboratory testing. The company's core business model revolves around routine, non-routine, and advanced diagnostics, serving physicians, hospitals, and consumers across the United States. Operating in the competitive healthcare diagnostics industry, DGX holds a strong market position alongside peers like LH, benefiting from steady demand for testing services amid aging populations and chronic disease prevalence. Its solid fundamentals, including consistent revenue growth and operational efficiency, underpin recent stock resilience despite sector volatility.
Over the last 30 days, from a closing price of approximately $194.41 on March 20 to $195.02 on April 17, DGX stock advanced +0.3%, reflecting a relatively flat, range-bound movement with low volatility ahead of earnings. In contrast, the past quarter saw a steadier uptrend, rising +3.2% from $188.95 on January 20 to the recent $195.02 close, driven by post-earnings momentum before a minor consolidation phase.
DGX stock's modest +0.3% gain over the past 30 days was influenced by anticipation surrounding the upcoming Q1 2026 earnings release on April 21, with analysts forecasting $2.81 billion in revenue and $2.34 EPS. The ex-dividend date on April 6 contributed to minor pressure, as shares adjusted post-payout of the increased quarterly dividend. Recent analyst actions, including Evercore ISI's price target adjustment to $210, supported sentiment amid broader market volatility. Sector trends in healthcare diagnostics provided a stable backdrop, though DGX slightly underperformed peers on select days.
The +3.2% quarterly rise was propelled by standout Q4 2025 results announced on February 10, featuring revenues of $2.81 billion, up 7.1% year-over-year, and adjusted diluted EPS of $2.42, surpassing expectations. A 7.5% dividend hike to $0.86 per share bolstered investor confidence, alongside Barclays' upgrade to overweight with a $210 target. Broader macroeconomic resilience in healthcare, including sustained testing volumes, offset any regulatory pressures. Positive institutional interest and a consensus "Moderate Buy" rating with an average target of $218 amplified the uptrend, culminating in year-to-date gains exceeding 13%.
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms trading thousands of tickers across various markets. This curated section highlights bots with the strongest recent performance and relevance, based on metrics like win rate, average return, and consistency across timeframes such as day trading, swing trading, or long-term strategies. Each bot employs unique approaches, from pattern recognition to momentum signals, enabling users to select tools aligned with their risk tolerance and goals. Explore these leading performers to enhance your trading toolkit today.
Investors should monitor Quest Diagnostics' Q1 2026 earnings on April 21 for insights into revenue growth, margins, and full-year guidance updates. Ongoing industry trends, such as advanced diagnostics adoption and reimbursement policies, could shape sentiment. Macroeconomic factors like healthcare spending and inflation impacts on operations remain key. Strategic developments, including potential partnerships or expansions, alongside analyst revisions and peer performance in diagnostics, warrant attention. Risks from regulatory changes or volume fluctuations in routine testing also merit vigilance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
DGX moved above its 50-day moving average on June 23, 2026 date and that indicates a change from a downward trend to an upward trend. In of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 25, 2026. You may want to consider a long position or call options on DGX as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for DGX just turned positive on June 25, 2026. Looking at past instances where DGX's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for DGX crossed bullishly above the 50-day moving average on June 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DGX advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 288 cases where DGX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DGX broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.910) is normal, around the industry mean (12.440). P/E Ratio (21.390) is within average values for comparable stocks, (145.998). Projected Growth (PEG Ratio) (1.490) is also within normal values, averaging (1.492). DGX has a moderately high Dividend Yield (0.017) as compared to the industry average of (0.008). P/S Ratio (1.935) is also within normal values, averaging (7.264).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. DGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of diagnostic testing and information services
Industry MedicalSpecialties